|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q1 FY2023
As of Mar 31, 2023
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturities, available-for-sale, at fair value (amortized cost: $260,225 and $236,299; no allowance for credit losses) | ||||||||||||||||||||
| Equity securities, at fair value (cost: $4,939 and $4,936) | ||||||||||||||||||||
| Equity securities, at fair value (cost: $4,943 and $4,939) | ||||||||||||||||||||
| Other invested assets (cost: $7,946 and $7,946) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Real estate | ||||||||||||||||||||
| Investment in unconsolidated trusts (cost: $1,238 and $1,238) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Receivables: | ||||||||||||||||||||
| Reinsurance (net of allowance for uncollectible reinsurance of $58 and $73) | ||||||||||||||||||||
| Insurance premiums and other (net of allowance for expected credit losses $189 and $201) | ||||||||||||||||||||
| Deferred income taxes, net | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Intangibles | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Insurance reserves and policyholder funds | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Losses and claims | ||||||||||||||||||||
| Other policy liabilities | ||||||||||||||||||||
| Total insurance reserves and policyholder funds | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Revolving credit facility | ||||||||||||||||||||
| Junior subordinated debenture obligations, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Preferred stock, $1 par, 4,000,000 shares authorized; Series D preferred, 55,000 shares issued and outstanding; $5,500 redemption value | ||||||||||||||||||||
| Common stock, $1 par, 50,000,000 shares authorized; 22,400,894 shares issued; $20,397,228 and 20,399,758 shares outstanding as of 2025 and 2024, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Unearned stock grant compensation | ||||||||||||||||||||
| Treasury stock, at cost, 2,003,666 and 2,001,136 shares as of 2025 and 2024, respectively | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
